Peer Review

GSK’s Moncef Slaoui joins the board at Moderna; Aduro promotes van Elsas to CSO

→  AnaptysBio CSO Matthew Moyle has abruptly resigned and left the company. An SEC filing notes he got nine months salary as severance.

Andrea van Elsas, the chief scientific officer of Aduro Biotech Europe, will be appointed chief scientific officer of the mother company Aduro Biotech in Berkley, CA.

→ Moncef Slaoui, the former R&D and vaccines chief at GlaxoSmithKline, is joining the board at the mRNA company Moderna. Slaoui is an enthusiastic champion of pioneering drug R&D. And he says he’s looking “forward to working with the team to navigate this uncharted territory, and support the strategic planning already underway as Moderna works to deliver mRNA medicines and vaccines to address serious unmet medical needs in the U.S. and globally.”

→ After a year of discontent, there’s been a change at the top of France’s National Research Agency as Michael Matlosz steps down.

→ Merrimack Pharmaceuticals has expanded its executive management team with the appointment of Thomas E. Needham to the position of chief business officer.

→ Abeona Therapeutics announced that Juan Ruiz has joined the company as chief medical officer.

→ PTC Therapeutics has promoted Joseph McIntosh to senior vice president and head of clinical development. McIntosh will be responsible for all aspects of Clinical Development across PTC’s portfolio.

→ Oxford Immunotec Global announced the appointment of Richard Wenstrup as chief medical officer.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Regulatory Convergence 2017